InflaRx N.V. Share Price Xetra

Equities

IF0

NL0012661870

Biotechnology & Medical Research

End-of-day quote Xetra 23:00:00 18/08/2022 BST 5-day change 1st Jan Change
2.939 EUR -.--% Intraday chart for InflaRx N.V. -.--% -.--%

Financials

Sales 2024 * 407K 444K 34.21M Sales 2025 * 1.37M 1.49M 115M Capitalization 89.56M 97.62M 7.53B
Net income 2024 * -45M -49.05M -3.78B Net income 2025 * -61M -66.49M -5.13B EV / Sales 2024 * 93.4 x
Net cash position 2024 * 51.55M 56.19M 4.33B Net cash position 2025 * 7.3M 7.95M 613M EV / Sales 2025 * 60 x
P/E ratio 2024 *
-2.06 x
P/E ratio 2025 *
-1.77 x
Employees 62
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.66%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on InflaRx N.V.

3 years
0.93
Extreme 0.93
5.09
5 years
0.93
Extreme 0.93
8.56
10 years
0.93
Extreme 0.93
8.56
More quotes
Managers TitleAgeSince
Founder 53 30/11/07
Founder 51 30/11/07
Director of Finance/CFO 59 30/09/20
Members of the board TitleAgeSince
Founder 51 30/11/07
Founder 51 30/11/07
Founder 53 30/11/07
More insiders
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.544 EUR
Average target price
7.435 EUR
Spread / Average Target
+381.60%
Consensus